Kalff Victor, Duong Cuong, Drummond Elizabeth G, Matthews Jane P, Hicks Rodney J
Center For Molecular Imaging, The Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
J Nucl Med. 2006 Jan;47(1):14-22.
Predicting outcome after aggressive therapy for advanced rectal cancer remains difficult. (18)F-FDG PET has emerged as a valid method for predicting patient outcomes after therapy in an increasing number of cancers. We evaluated the prognostic information obtained from the degree of change in tumor (18)F-FDG PET uptake induced by chemoradiation before radical curative surgery in patients with T3/T4 rectal cancer.
The study included 34 consecutive patients with T3/T4 Nx M0 rectal cancer on structural imaging, who underwent staging and postchemoradiation (18)F-FDG PET before planned curative surgery. Change in (18)F-FDG uptake was graded visually as complete (CMR), partial (PMR), or no (NoMR) metabolic response. Pre- and postchemoradiation (18)F-FDG PET-derived standardized uptake values (SUVs) were then obtained for PMR patients to determine whether SUV further stratified this subgroup. Operative findings were available in 30 patients (3 excluded because of (18)F-FDG PET-defined M1 disease, 1 refused surgery). Clinical status at study closeout (alive free from disease, FFD; alive with disease, AWD; or died of disease, DOD) was available for all patients.
A pathologic complete response was found in only 6 of 30 patients (5 CMR, 1 false-positive PMR). However, after an estimated median 3.1 y of follow-up, all 17 CMR patients were FFD, 6 of 10 PMR patients were FFD, 2 of 10 had DOD, and 2 of 10 were AWD. All 3 NoMR patients DOD. PET response was highly significantly associated with overall survival duration (P < 0.0001) and time to progression (P < 0.0001). Pathologic complete response was the only other statistically significant prognostic factor (P < 0.03). The percentage of maximum SUV change after chemoradiation was not predictive of survival in PMR patients.
Using a simple qualitative assessment, postchemoradiation (18)F-FDG PET scintigraphy provides good medium-term prognostic information in patients with advanced rectal cancer undergoing radical surgery with curative intent.
预测晚期直肠癌积极治疗后的结果仍然困难。(18)F-FDG PET已成为预测越来越多癌症患者治疗后结果的有效方法。我们评估了T3/T4期直肠癌患者在根治性手术前通过放化疗诱导的肿瘤(18)F-FDG PET摄取变化程度所获得的预后信息。
该研究纳入了34例经结构成像诊断为T3/T4 Nx M0期直肠癌的连续患者,这些患者在计划的根治性手术前行分期及放化疗后(18)F-FDG PET检查。(18)F-FDG摄取变化通过视觉分级为完全代谢缓解(CMR)、部分代谢缓解(PMR)或无代谢缓解(NoMR)。然后获取PMR患者放化疗前后(18)F-FDG PET衍生的标准化摄取值(SUV),以确定SUV是否能进一步对该亚组进行分层。30例患者有手术结果(3例因(18)F-FDG PET定义的M1期疾病被排除,1例拒绝手术)。所有患者均有研究结束时的临床状态(无病存活,FFD;带病存活,AWD;或死于疾病,DOD)。
30例患者中仅6例出现病理完全缓解(5例CMR,1例假阳性PMR)。然而,经过估计中位3.1年的随访,17例CMR患者均为FFD,10例PMR患者中有6例为FFD,10例中有2例DOD,10例中有2例AWD。3例NoMR患者均DOD。PET反应与总生存时间(P < 0.0001)和疾病进展时间(P < 0.0001)高度显著相关。病理完全缓解是唯一另一个具有统计学意义的预后因素(P < 0.03)。放化疗后最大SUV变化百分比不能预测PMR患者的生存。
通过简单的定性评估,放化疗后(18)F-FDG PET闪烁扫描可为有根治性手术意向的晚期直肠癌患者提供良好的中期预后信息。